New rules will allow EU patients to report drug concerns directly
BMJ 2010; 341 doi: https://doi.org/10.1136/bmj.c5344 (Published 28 September 2010) Cite this as: BMJ 2010;341:c5344- Rory Watson
- 1Brussels
Patients will be better informed about drugs and be able to report any adverse effects directly to national authorities, after the European parliament overwhelmingly agreed new legislation on 22 September.
Under the new pharmacovigilance requirements, which will apply across the European Union, national web portals will have to be established to provide the public with information on medicinal products and any known side effects. The portals will contain assessment reports, summaries of product characteristics, information leaflets, and advice for patients on how to report any concerns they might have.
The national portals will be linked …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.